- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06125951
알츠하이머병으로 인한 치매에 대한 10mg Xanam의 효과 (XanaMIA)
알츠하이머병으로 인한 경증 또는 중등도 치매 환자를 대상으로 매일 Xanamem® 10mg의 안전성, 내약성 및 효능을 평가하기 위한 2b상, 이중 맹검, 위약 대조, 병렬 그룹, 36주, 2군 시험
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be eligible to participate in an open-label phase, which involves treatment with 10mg Xanamem once daily for a treatment period of up to a maximum of 108 weeks. The OLE is intended to finish when all participants have completed at least 60 weeks of treatment and a follow-up visit 4 weeks later.
연구 개요
연구 유형
등록 (실제)
단계
- 2 단계
- 3단계
연락처 및 위치
연구 장소
-
-
California
-
Carlsbad, California, 미국, 92011
- ACW Investigative Site 218
-
Sherman Oaks, California, 미국, 91403
- ACW Investigative Site 209
-
-
Colorado
-
Denver, Colorado, 미국, 80218
- ACW Investigative Site 211
-
Englewood, Colorado, 미국, 80113
- ACW Investigative Site 208
-
-
Florida
-
Delray Beach, Florida, 미국, 33445
- ACW Investigative Site 203
-
Miami, Florida, 미국, 33176
- ACW Investigative site 201
-
New Port Richey, Florida, 미국, 34652
- ACW Investigative site 202
-
Orlando, Florida, 미국, 32803
- ACW Investigative site 204
-
The Villages, Florida, 미국, 32162
- ACW Investigative site 205
-
-
Georgia
-
Decatur, Georgia, 미국, 30030
- ACW Investigative Site 207
-
-
New Jersey
-
Marlton, New Jersey, 미국, 08053
- ACW Investigative Site 206
-
-
New York
-
Albany, New York, 미국, 12208
- ACW Investigative Site 214
-
Staten Island, New York, 미국, 10314
- ACW Investigative Site 219
-
-
Ohio
-
Dayton, Ohio, 미국, 45459
- ACW Investigative Site 210
-
Independence, Ohio, 미국, 44131
- ACW Investigative Site 217
-
-
Oregon
-
Portland, Oregon, 미국, 97225
- ACW Investigative Site 212
-
-
Rhode Island
-
East Providence, Rhode Island, 미국, 02914
- ACW Investigative Site 216
-
-
Texas
-
Austin, Texas, 미국, 78757
- ACW Investigative Site 220
-
-
Washington
-
Bellevue, Washington, 미국, 98007
- ACW Investigative Site 215
-
-
-
-
New South Wales
-
Darlinghurst, New South Wales, 호주
- ACW Investigative Site 106
-
Erina, New South Wales, 호주
- ACW Investigative Site 103
-
Kogarah, New South Wales, 호주
- ACW Investigative Site 102
-
Macquarie Park, New South Wales, 호주
- ACW Investigative Site 107
-
Newcastle, New South Wales, 호주
- ACW Investigative Site 111
-
-
Queensland
-
Birtinya, Queensland, 호주
- ACW Investigative Site 113
-
Chermside, Queensland, 호주
- ACW Investigative Site 105
-
-
South Australia
-
Bedford Park, South Australia, 호주
- ACW Investigative Site 114
-
Woodville South, South Australia, 호주
- ACW Investigative Site 110
-
-
Victoria
-
Carlton, Victoria, 호주
- ACW Investigative Site 115
-
Ivanhoe, Victoria, 호주
- ACW Investigative Site 101
-
Malvern, Victoria, 호주
- ACW Investigative Site 108
-
Parkville, Victoria, 호주
- ACW Investigative Site 112
-
-
Western Australia
-
Nedlands, Western Australia, 호주
- ACW Investigative Site 104
-
West Perth, Western Australia, 호주
- ACW Investigative Site 109
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Male or female aged 50 years or older, inclusive at the time of Screening.
-
Clinical syndrome of mild or moderate dementia, likely to be due to AD in the opinion of the Investigator, at Screening, including meeting the following criteria:
- Clinical Dementia Rating (CDR) global score of 0.5 to 1.0
- Mini-mental state examination (MMSE) score of 18 to 26
- Magnetic resonance imaging (MRI) or computerized tomography (CT) scan within 1 year prior to randomization that excludes alternative diagnoses for dementia such as large stroke, likely vascular dementia, brain tumor, subdural hematoma, or other non-AD dementia type findings
- Positive plasma AD biomarker signature at Pre-screening, comprising fasting levels of a tau species protein.
-
If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to Screening.
-
Has a consenting trial partner who, in the Investigator's judgment, has frequent and sufficient contact with the participant to be able to provide accurate information as to the participant's cognitive and functional abilities. The trial partner must be available to provide information to the Investigator and trial site staff about the participant and agrees to attend all trial site visits in person for scale completion. A trial partner should be available for the duration of the trial. The measure of adequate availability will be at the Investigator's discretion.
-
Participants must be able to comfortably abstain from caffeine intake for 4 hours prior to scheduled cognitive assessments.
-
Smokers are eligible if they are able to comfortably abstain from nicotine / tobacco products for 2 hours prior to scheduled cognitive assessments.
-
Must provide written informed consent to participate in the trial and be willing and able to participate for the maximum of 9 months of treatment and up to 11.5 months of site visits.
Exclusion Criteria:
- Use of anti-amyloid or anti-tau antibody within 6 months.
- Diagnosis of a non-AD dementia including traumatic brain injury.
- Diagnosis of an active major mental illness of concern in the opinion in the Investigator, including major depressive disorder, bipolar illness, or schizophrenia.
- Participation in another clinical trial of a drug or device
- Has a body mass index or body weight that will interfere with participation in the trial, including inadequate venous access to complete the trial assessments, to be determined at the discretion of the Investigator.
- Previous clinically significant systemic illness or infection, including test positive COVID-19, within the past 4 weeks prior to Screening.
- Clinical diagnosis of Type I or Type II diabetes requiring insulin.
- Exhibit physical, cognitive, or language impairments, in the opinion of the Investigator, of such severity as to adversely affect the validity of the data derived from the neuropsychological tests.
- Trial participants with evidence of current infection with HIV, hepatitis B, or hepatitis C.
- Participants with a history of clinically significant drug abuse or addiction in the past 2 years
- Evidence or history of alcohol abuse
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 10 mg Xanamem
10 mg Xanamem tablet, to be administered orally once every morning with or without food |
Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
다른 이름들:
|
|
위약 비교기: Placebo
Placebo tablet, to be administered orally once every morning with or without food |
Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient. |
|
실험적: Open label phase
Participants enrolled in the open-label phase after the main trial will receive 10 mg Xanamem, to be administered orally once every morning with or without food |
Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Effects of 10 mg Xanamem on integrated cognitive and functional abilities
기간: 36 weeks
|
Change from Baseline to end of treatment (EOT) in the Clinical Dementia Ratio - Sum of Boxes (CDR-SB). The CDR-SB is calculated as an average score, with lower scores indicating improvement. |
36 weeks
|
|
Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem]
기간: 36 weeks
|
Incidence and severity of TEAEs |
36 weeks
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Global Program Lead, Actinogen Medical Ltd
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .